BACKGROUND:Latest researches suggest that delayed endothelial repair in drug-eluting stents may cause thrombosis and coronary occlusion.Therefore,a novel kind of drug stent,which is characterized by satisfactory anti-proliferative action as well as inhibitive effects on thrombosis,needs to be developed.OBJECTIVE:To summarize the recent research progress and clinical applications of drug-eluting stents (DES) and to seek the direction of new developments.RETRIEVE STRATEGY:The retrieve staffs were the research personnel for this paper.A computer-based online search was conducted in PUBMED for English language publications containing the key words of "drug eluting stents,percutaneous coronary intervention,coronary disease" from January 2002 to April 2007.Relevant data were also searched in international conference reports on the Internet between January 2005 and June 2007.The number of total retrieved Iiteratures was 15.Inclusion criteria:①reports about drug stents;②reports on research progress in the field of drug stents;③reports on the clinical application of drug stents.Exclusion criteria:low relevance and duplicated articles.LITERATURE EVALUATION:There were 264 articles about research and clinical applications of DES.Of those,42 literatures and 5 conference reports with high relevance and timeliness were included in this report.DATA SYNTHESIS:An ideal DES is comprised of a platform,a drug carrier vehicle and a pharmaceutical compound in harmony with each other.Given the ongoing development of DES materials and drugs,more effective DESs are introduced in the clinical practice.Recently,clinical data on DES encourage the interventional cardiologist to use DES in more challenging coronary lesions,such as chronic total occlusions,complex lesions and multivessel lesions.However,concern that DES may be associated with a risk of late thrombotic events arose,suggesting an imbalance between safety and efficacy of DES.Therefore,novel strategies including bioabsorbable stents,and stents coated with pro-healing agents are promising.CONCLUSION:The development of DES is a breakthrough in interventional cardiology that bring great benefit to patients with coronary disease,especially for restenosis and revascularization.Nevertheless,more endeavour will be necessary to create DES with high efficacy as well as low risk.

Soluble ST2 ( sST2 ) is protein of interleukin-1 ( IL-1 ) receptor family present in the blood which have been identified has the ability to capture IL-33, thereby inhibiting IL-33/ST2 signaling, the mechanical properties overload of myocardial cells was significantly increased .Thus, when at the onset of heart failure or chronic heart failure deteriorated , or at scarring resulted by myocardial infarction , soluble ST2 can be detected in the blood .The purpose of this review is to discuss the role of soluble ST 2 ( sST2) as a new cardiovascular marker.

Stem cell therapy for myocardial repair after myocardial infarction is a new and promising treatment modality.But the mechanism is still not very clear.Currently,stem cells are used in clinical study to evaluate its beneficial effect on repairing infarcted/hibernating myocardium after myocardial infarction and heart failure.But there is no final conclusion on the safety of stem cell transplantation.

First of all,all tutors as well as postgraduates should have concept of innovation.Secondly,favorable environment should be built up for innovative thoughts.Finally,tutors should try their best to cultivate students'innovative thoughts and direct their creationary practice.

Aortic Valve Insufficiency ; therapy ; Heart Valve Prosthesis ; Heart Valve Prosthesis Implantation ; Humans ; Transcatheter Aortic Valve Replacement

Objective To investigate the effect of purified single clonally mesenchymal cells (SCMSCs) on cardiac function in rat models and also try to find out wheter SCMSCs serve as a better source for transplantation than UMSCs, BM-MNCs and PB-MNCs. Methods SCMSCs were isolated, cultured, purified, cloned and expanded. UMSCs were isolated primarily by their tight adherence to the culture dishes. BM-MNCs and PB-MNCs were prepared by Ficoll-Hypaque gradient centrifugation. All cell characters were verified by fluorescence- activated cell sorter (FACS). A total of 5?10~6 PB-MNCs, BM-MNCs, UMSCs, and SCMSCs were transplanted into the ischemic zone immediately after MI. The cardiac function was evaluated by hemodynamic technique 1 month after the transplantation. The vessel density and cell differentiation were determined by histological techniques. Results SCMSCs expressed over 99% of the mesenchymal cell surface protein and none of the hematopoietic stem cell surface protein. Hemodynamics showed that transplantation of snMSC led to the greatest improvement in cardiac function, compared with PB-MNCs, BM-MNCs, and UMSCs transplantation. In consistence with cardiac function recovery, SCMSCs transplantation resulted in the greatest angiogenesis in the ischemic wall, and the greatest number of transplanted SCMSCs expressed these cardiomyocyte proteins, or vascular endothelial cell marker, in comparison with the other heterogeneous cells. Conclusion Transplantation of single clonally purified non-hematopoietic mesenchymal stem cells from human bone marrow showed the greatest imporvement in cardiac function compared to UMSC, BM-MNC, and PB-MNC in this study.

0.05) in the BMT group but significantly enlarged in the CON group (50.4?6.0 mm vs. 55.2?7.1 mm, P

Objective To evaluate the safety and efficacy of homemade patent ductus arteriosus (PDA) closure device for patients with very large PDA. Methods A total of 15 patients (12 females) with very large PDA, underwent transcatheter occlusion with homemade PDA devices. The median age was 21?8 (16-46) years old. The median diameter of the PDA at its narrowest point was 16?3 (13-22) mm. Aortic angiography and measurement of pulmonary pressure were performed before and after the closure of PDA. Repeat echocardiography was performed on each patient at one week, one month and six months after the procedure. Results Fifteen patients underwent transcatheter closure using a device of 23?4 (18-32)mm in diameter, and all of them showed a trace to small shunt by aortic angiography 30 minutes after the procedure. Thirteen patients was successfully occluded with a peak systolic pulmonary pressure decreased from 113?21 mm?Hg to 70?29 mm?Hg (P

Objective To investigate the effects of emodin on the migration and proliferation of vascular smooth muscle cell (VSMC) and the metabolism of emodin in VSMC. Methods The effects of emodin on the migration or proliferation of vascular smooth muscle cell were measured by “transwell" migration system and MTT assay. Results The migration of VSMC could be significantly inhibited by emodin and the inhibitory ratio was 83.8% in 5 ?g/mL emodin group. The antiproliferative effect of emodin was in a dose- and time- dependent manner. However, the supernatant concentration of emodin insignificantly dereased after culture for 24 h. The cytotoxicity of emodin and cellular ROS was not influenced by CYP inducer or inhibitor. The mRNA expression of emodin's primary metabolic enzyme (cytochrome p450 oxidase, CYP) up-regulated insignificantly after treatment of emodin for 24 h. Conclusion Emodin can inhibit the migration and proliferation of VSMC and can not be metabolized by VSMC. Emodin may be a choice for the medication of drug-eluting stent.

Objective To investigate whether host collateral vessels play a role in the cardiac repair induced by intracoronary injection of bone marrow mononuclear cell (BMMNCs) in a swine myocardial infarction (MI) model. Methods MI was induced in swine models by ligation of left anterior descending artery. Two weeks later, twenty animals with Rentrop score=0 (R0) or Rentrop score=1 (R1) received either intracoronary PBS or BM-MNCs (2?10~8 cells) infusion. Results At 6 weeks after MI, Rentrop score was significantly increased in the R1+BMT group. Ejection fraction and fractional shortening evaluated by echocardiography were increased in both R0+BMT and R1+BMT groups and the greatest improvements were seen in the R1+BMT group. Consistent with the changes in cardiac function and Rentrop score, the greatest degree of angiogenesis and cell count of engrafted BM-MNCs occurred in the R1+BMT group 6 weeks post MI. Conclusion The existence of intrinsic collateral vessels contributes to the beneficial effects for cardiac repair post MI by intracoronary BM-MNCs transplantation.